LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on VYNE Therapeutics today and set a price target of $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding VYNE Therapeutics’ promising developments in the treatment of nonsegmental vitiligo (NSV). The company’s Phase IIb trial of repibresib gel is on track, with topline data expected by mid-2025, marking a significant milestone. The Phase Ib study showed that repibresib gel, at both 1% and 2% concentrations, provided rapid and meaningful clinical benefits with a favorable safety profile and limited systemic exposure.
The ongoing Phase IIb trial is expanding on these findings by testing a higher concentration of 3%, extending the evaluation period to 24 weeks, and including both active and stable disease subjects. This approach could differentiate repibresib from existing JAK inhibitors. Dr. Desai, a key opinion leader, expressed optimism about repibresib’s potential due to its novel mechanism, once-daily dosing, and anticipated lack of a black box warning, suggesting it could be a valuable addition to treatment options even if its efficacy is slightly lower than competitors.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 18.3% and a 50.56% success rate on recommended stocks.
In another report released on July 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.